Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew P Goetz

Showing results (141-150 of 265) with videos related to

Pageof 27
Sort By:
Breast Cancer Research and Treatment|October 21, 2024
CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108Vered Stearns, Anne ONeill, Bryan P Schneider, et al.
Investigational New Drugs|October 12, 2013
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabineMatthew P Goetz, Heidi A McKean, Joel M Reid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2023
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast CancerMatthew P Goetz, Erika P Hamilton, Mario Campone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashesMatthew P Goetz, James M Rae, Vera J Suman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2025
Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II TrialThomas E Mürdter, Werner Schroth, Matthew P Goetz, et al.
Scientific Reports|January 12, 2023
PDJ amplicon in triple negative breast cancerAlexander S Roesler, Smriti Malasi, Lori Koslosky, et al.
Pharmacogenetics and Genomics|February 26, 2015
Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifenStephanie L Safgren, Vera J Suman, Matthew L Kosel, et al.
Cell Metabolism|September 4, 2018
Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle PathwayKiran Kurmi, Sadae Hitosugi, Jia Yu, et al.
Breast Cancer Research : BCR|November 23, 2017
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclibNusayba Bagegni, Shana Thomas, Ning Liu, et al.
Breast Cancer Research : BCR|January 3, 2024
Identification of a Notch transcriptomic signature for breast cancerEike-Benjamin Braune, Felix Geist, Xiaojia Tang, et al.
Pageof 27

Showing results (141-150 of 265) with videos related to

Sort By:
Pageof 27
Breast Cancer Research and Treatment|October 21, 2024
CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108Vered Stearns, Anne ONeill, Bryan P Schneider, et al.
Investigational New Drugs|October 12, 2013
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabineMatthew P Goetz, Heidi A McKean, Joel M Reid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2023
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast CancerMatthew P Goetz, Erika P Hamilton, Mario Campone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashesMatthew P Goetz, James M Rae, Vera J Suman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2025
Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II TrialThomas E Mürdter, Werner Schroth, Matthew P Goetz, et al.
Scientific Reports|January 12, 2023
PDJ amplicon in triple negative breast cancerAlexander S Roesler, Smriti Malasi, Lori Koslosky, et al.
Pharmacogenetics and Genomics|February 26, 2015
Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifenStephanie L Safgren, Vera J Suman, Matthew L Kosel, et al.
Cell Metabolism|September 4, 2018
Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle PathwayKiran Kurmi, Sadae Hitosugi, Jia Yu, et al.
Breast Cancer Research : BCR|November 23, 2017
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclibNusayba Bagegni, Shana Thomas, Ning Liu, et al.
Breast Cancer Research : BCR|January 3, 2024
Identification of a Notch transcriptomic signature for breast cancerEike-Benjamin Braune, Felix Geist, Xiaojia Tang, et al.
Pageof 27